We continue to focus on research and development for other disease
areas of significant need, always with an improved quality of life for
patients in mind.
We are dedicated to researching, developing and providing additional
therapies for the gynecologic care of women. Our drive to innovate and
expand the medical treatment available is focused in two key areas of
women’s health: contraceptives that increase the options available to
help meet individual care preferences, and oral medications to manage
the acute menstrual health conditions of endometriosis and uterine
Cystic fibrosis (CF) is a rare, life-threatening, genetic disease
that affects between 70,000 and 100,000 patients worldwide. In the US
and UK, average life expectancy is 35 to 40 years old. In countries
such as El Salvador, India and Bulgaria, life expectancy drops to
below 15. There currently is no cure for CF. We are currently
evaluating investigational compounds in early clinical phases for a
triple combination therapy.
Diabetic nephropathy, or diabetic kidney disease, is a common
complication of diabetes and the leading cause of chronic kidney
disease in the developing world. We are currently conducting a
clinical study to assess the effects of an investigational drug on
progression of kidney disease in patients with stage 2 to 4 CKD and
type 2 diabetes.